Geron Corporation (GERN)
NASDAQ • Healthcare
Last close at September 4, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Geron Corporation currently loses $29.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 61 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Geron Corporation
Geron Corporation is a NASDAQ-listed biotechnology company focused on imetelstat, a telomerase inhibitor for blood cancers. In FY2025, the company generated $183.9 million in revenue. Geron develops its therapy within the healthcare sector around a single oncology asset designed to target malignant cell biology.
Today's Snapshot
The day ended with GERN 4% higher at 1.57, outperforming a weaker sector.
Trading Volume
Above 10d avg 11.4M
11.4M
vs S&P 500 Today
Strong Outperformance
+4.39%
Updated: September 4, 2026 at 20:08 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1.42 - $1.53Buy
- RSI (14)55.32Neutral
- Stochastic %K (14, 3, 3)64.81Neutral
- MACD Level (12, 26)0.02Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.